David Esposito
Vascular Surgery · Milford, CTNPI 1386669786
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 387 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for vascular surgery clinicians in CT, where the typical reported total is $7,252.
Across 387 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Boston Scientific$2K
- Medtronic$627
- Smith+Nephew$555
- Johnson & Johnson$482
- Paratek Pharmaceuticals, Inc.$362
- plus $2K from 27 others
What the payments were for
- Consulting fees$1001%
- Food & beverage$7,13298%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 142 | $1,615 |
| Boston Scientific | 73 | $1,560 |
| Medtronic(2 entities) | 19 | $627 |
| Smith+Nephew | 28 | $555 |
| Johnson & Johnson | 21 | $482 |
| Paratek Pharmaceuticals, Inc. | 24 | $362 |
| CSL Behring | 14 | $342 |
| Pfizer | 13 | $219 |
| Merck | 5 | $158 |
| Angiodynamics, Inc. | 6 | $150 |
| Lemaitre Vascular, Inc. | 3 | $128 |
| Boehringer Ingelheim | 1 | $122 |
| Avinger Inc. | 1 | $100 |
| Comsort, Inc | 1 | $100 |
| Tactile Systems Technology Inc | 5 | $85 |
| Solventum Corporation | 3 | $84 |
| W. L. Gore & Associates, Inc. | 1 | $82 |
| Inspire Medical Systems, Inc. | 2 | $62 |
| Reprise Biomedical, Inc. | 3 | $56 |
| Abbott | 2 | $50 |
| Bard Peripheral Vascular, Inc. | 5 | $46 |
| Philips North America LLC | 2 | $37 |
| Melinta Therapeutics, LLC | 2 | $34 |
| Acelrx Pharmaceuticals, Inc. | 1 | $26 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $26 |
| Terumo Medical Corporation | 1 | $24 |
| Organogenesis Inc. | 1 | $21 |
| Biocompatibles, Inc. | 1 | $19 |
| Urgo Medical North America, LLC | 1 | $19 |
| Next Science LLC | 1 | $17 |
| Shockwave Medical, Inc | 1 | $17 |
| Venturemed Group, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,252 in reported general payments places this provider in the 50th percentile of 82 vascular surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $112,686 |
| XareltoRivaroxaban | 47 | $38,455 |
| Cilostazol | 67 | $1,371 |
| ClopidogrelClopidogrel Bisulfate | 150 | $670 |
| Pentoxifylline | 29 | $561 |
| Oxycodone Hcl | 25 | $439 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 41 | $373 |
| Silver Sulfadiazine | 16 | $162 |
| Gabapentin | 31 | $162 |
| Atorvastatin Calcium | 20 | $88 |
| Furosemide | 12 | $16 |
| Alprazolam | 13 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $219 | $112,686162 claims |
| Johnson & JohnsonXarelto | $482 | $38,45547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 82 vascular surgery providers in Connecticut.
Other vascular surgery in Milford
- Uwe FischerNew London$941K
- Paul GagneDarien$766K
- Naiem NassiriNew Haven$348K
- Lee GoldsteinStratford$272K
- Mohiuddin CheemaHartford$228K
- Bauer SumpioNew Haven$205K
- Javairiah FatimaDanbury$152K
- Bart MuhsOld Saybrook$66K
- Jonathan BowmanDarien$53K
- Maria LitzendorfManchester$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.